<![CDATA[Lenvatinib Combo Holds Ground Against HER2 ADCs in Endometrial Cancer]]>

Data ReadoutlenvatinibpembrolizumabHER2-targeted ADCsPositive

AI Analysis

Summary

Lenvatinib plus pembrolizumab maintains clinical utility in recurrent endometrial cancer as a non-biomarker-directed approach, despite emergence of HER2-targeted antibody-drug conjugates in the treatment landscape.

Importance:4/10

Sentiment:

0.30

endometrial cancerlenvatinibpembrolizumabHER2-targeted therapycombination therapyoncology

Related Companies

$ESALY $MRK

Read the original article

Published by Cancer Network on August 24, 2026 8:00 PM

Read Original